Iceland· IS-EU/1/23/1736/001 & 011
Omvoh
A mirikizumab product containing mirikizumab, registered in Iceland by Eli Lilly Nederland B.V.*. The same ATC class is registered in 13 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Mirikizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC L04AC24 (mirikizumab), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Mirikizumab · ATC L04AC24
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of mirikizumab costs, country by country.
Normalised to the WHO defined daily dose (7.1 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Mirikizumab · price per daily dose (7.1 mg)
USD · FX 28 Sept 2026
- CH Switzerland$30.99
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Mirikizumab
- Manufacturer
- Eli Lilly Nederland B.V.*
- Country
- Iceland (IS)
- ATC code
- L04AC24
- ATC class
- Mirikizumab
- Defined daily dose
- 7.1 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mirikizumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaOMVOHEli Lilly Nederland B.V., Utrecht
- FinlandOmvohAbacus Medicine A/S
- BelgiumOmvoh 300 mgEli Lilly Nederland
- IrelandOmvoh 300 mg concentrate for solution for infusionEli Lilly Nederland B.V.
- NorwayOmvohEli Lilly Nederland B.V.
- SwedenOmvoh 300 mg Koncentrat till infusionsvätska, lösningEli Lilly Nederland B.V.
- United StatesOmvohEli Lilly and Company
- SwitzerlandOmvoh 100 mg + 200 mg, solution injectable en seringue préremplieEli Lilly (Suisse) SA
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Omvoh
- Norway · Omvoh
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e1a87b9b-f0e7-4480-9fab-9265af043d57 GET /v1/drugs/e1a87b9b-f0e7-4480-9fab-9265af043d57?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Innrennslisþykkni, lausn",
"source": "lyfjastofnun",
"atc_raw": "L04AC24",
"marketed": false,
"strength": "300 mg",
"ma_number": "EU/1/23/1736/001 & 011",
"substance": "Mirikizumab",
"other_info": null,
"legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
"ma_issued_serial": "45072"
}See everything about mirikizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.